Alpha-synuclein Transgenic Mouse Models
Test potential therapeutics for Parkinson’s disease and other synucleinopathies using InnoSer’s Alpha-synuclein Transgenic Mouse Models with alpha-synuclein deposition and downstream pathological events
Parkinson’s disease (PD) is a neurodegenerative disorder that affects the motor systems in early stages, leading to symptoms such as trembling, slowing of movement, and muscle stiffness. The distinct disease mechanism can be modelled in different Parkinson’s disease mouse models. Alpha-synuclein (α-syn) inclusions are the main histopathological hallmark correlating with clinical symptoms of not only PD, but also other synucleinopathies such as dementia with Lewy bodies (DLB), and multiple systems atrophy (MSA).
InnoSer offers fee-for-service alpha-synuclein (α-syn) transgenic mouse models. Accordingly, alpha-synuclein transgenic mouse models faithfully recapitulate the α-syn pathophysiology found in PD, DLB and MSA. As various models of α-syn pathology are available; the choice of the model ultiamtely depends on your compound’s mechanism of action and your research goals. Moreover, InnoSer offers research services with multiple other Parkinson’s disease mouse models, including alpha-synuclein seeding models and the MPTP mouse model. As each model is unique, modelling distinct pathophysiological aspects of PD, we recommend you discuss the most appropriate model with our neurology study directors.
Take advantage of InnoSer’s behavioural research expertise, flexibility, and collaborative approach for your research. Our in-house neurology experts have long-standing experience modelling PD in vivo using transgenic mouse lines and other neurodegenerative diseases. Our neurology experts help guide your decision on choosing the best model fit for your current research goals.
InnoSer’s neurology expert team possesses relevant experience in working with multiple therapy types ranging from small molecules, peptides, enzymes, oligonucleotides, gene therapy (viral vectors – e.g.. AAVs) and immunotherapies (antibody/vaccine immunotherapies).
Alpha-synuclein transgenic mouse models that InnoSer offers:
- Human α-syn models.
- A53T α-syn models (e.g. M83).
- Seeding in α-syn transgenic models.
Find the right model for you.
Compare our model capabilities and discover which of our neurology platforms suits your research needs
Key readouts in alpha-synuclein transgenic mouse models
Test the efficacy of your treatments in the following battery of behavioural tests:
Test the efficacy of your treatments with the following biological readouts:
- MSD: Plasma, CSF and brain (α-syn, cytokines, NfL)
- (Digital) histopathology
- Immunohistochemistry (e.g. α-syn, neuroinflammation, neurodegeneration)
- Immunofluorescence and FISH
Example data featuring alpha-synuclein transgenic mouse models
Homozygous M83+/+ A53T (aSyn) transgenic mice show increased slips on the Balance beam at 8 months of age, compared to WT controls.
The Balance Beam sensorimotor coordination test scores the ability of mice to traverse a stationary horizontal rod. Coordination of the mouse is measured by the latency to cross the beam and the number of foot slips made.
Related Parkinson’s Disease model options
Neurology Platform Overview
Seeding Alpha-Synuclein Models
MPTP Mouse Model of Parkinson’s Disease
InnoSer offers unique services using MPTP-based inducible PD models.
AAALAC Accreditation
InnoSer has earned the AAALAC accreditation, demonstrating our commitment to responsible animal care and use. AAALAC International is a nonprofit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. Our accreditation is valid for three years, incl. 2023. Read more about the AAALAC accreditation programme here.
Animal Welfare
The 3Rs impact everything from policy and regulatory change to the development and uptake of new technologies and approaches. This is why InnoSer has ongoing commitment and monitoring of these processes. The steps we practice maximize our ability to replace, reduce and refine animal involvement and facilitate our commitment to these principles when it comes to research and drug development.
Need more information?
If you have any questions about how we can help accelerate your research,
then let us know